Showing 1 - 4 results of 4 for search 'Macaya Douoguih', query time: 0.02s Refine Results
  1. 1
    A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks

    A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks by Georgi Shukarev, Benoit Callendret, Kerstin Luhn, Macaya Douoguih, the EBOVAC1 consortium

    Published 2017
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults

    Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults by Macaya Douoguih, Neil Goldstein, Stephan Bart, Kerstin Luhn, Wilbert Van Duijnhoven, Carla Truyers, Benoit Callendret

    Published 2016
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

    Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial by Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Linda Bus-Jacobs, Jenny Hendriks, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  4. 4
    Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age

    Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in in... by Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P. Cahill, Hanneke Schuitemaker, Macaya Douoguih, Jeanne-Marie Jacquet

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: